BioSpace News Archive

Syros Pharmaceuticals today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a corporate restructuring to reduce costs and more closely align operating expenses with expected revenue.

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced that members of the management team will participate in the following upcoming investor conferences.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET.

Dermavant Sciences today announced that the first patient has been dosed in a Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD).

Vonco Products Receives FDA 510(k) Clearance for Novel Closed-Loop Enteral Feeding Solution - EnteraLoc™ Flow

GemPharmatech (GemPharmatech Co., Ltd. “GPT”) presented its humanized mouse models to support T-Cell Bispecific antibody and COVID-19 preclinic development and co-hosted a panel discussion on bispecific antibodies at Biologics UK Oxford Global Conference, London, UK, Sept. 6-8, 2021

Entos, Inc. today announced that it has appointed Jack Taunton, Professor of Cellular Molecular Pharmacology at University of California, San Francisco, and Ken Brameld, Senior Advisor for Samsara Biocapital, to the Company’s Scientific Advisory Board.

Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System

Oramed Pharmaceuticals Inc. announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, on September 13, 2021.